Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
31777 | 148 | 19.5 | 46% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
8 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1276458 |
131 | 3 | HEMATOLOGY//HAEMOPHILIA//TRANSFUSION | 66936 |
966 | 2 | CLOPIDOGREL//PRASUGREL//TICAGRELOR | 10690 |
31777 | 1 | INDOBUFEN//CAS 106498991//INDOBUFEN ENANTIOMERS | 148 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | INDOBUFEN | authKW | 982471 | 7% | 48% | 10 |
2 | CAS 106498991 | authKW | 412642 | 1% | 100% | 2 |
3 | INDOBUFEN ENANTIOMERS | authKW | 412642 | 1% | 100% | 2 |
4 | VINTOPEROL PHARMACOLOGY | authKW | 412642 | 1% | 100% | 2 |
5 | 2 2 3 4 5 TRIMETHOXYBENZOYLOXYETHYLPYRROLIDINE HYDROCHLORIDE | authKW | 206321 | 1% | 100% | 1 |
6 | 6 KETO PGF 1 ALPHA | authKW | 206321 | 1% | 100% | 1 |
7 | 90 OMEGA 3 POLYUNSATURATED FATTY ACID PFA | authKW | 206321 | 1% | 100% | 1 |
8 | ANTIAGGREGANT TREATMENT | authKW | 206321 | 1% | 100% | 1 |
9 | ANTITHROMBOTIC COMPOUND | authKW | 206321 | 1% | 100% | 1 |
10 | ASA HYPERSENSITIVITY | authKW | 206321 | 1% | 100% | 1 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Pharmacology & Pharmacy | 694 | 41% | 0% | 60 |
2 | Hematology | 427 | 17% | 0% | 25 |
3 | Peripheral Vascular Diseases | 389 | 16% | 0% | 23 |
4 | Medicine, Research & Experimental | 300 | 18% | 0% | 26 |
5 | Chemistry, Multidisciplinary | 116 | 20% | 0% | 30 |
6 | Chemistry, Medicinal | 18 | 4% | 0% | 6 |
7 | Cardiac & Cardiovascular System | 11 | 5% | 0% | 7 |
8 | Chemistry, Analytical | 8 | 5% | 0% | 7 |
9 | Integrative & Complementary Medicine | 3 | 1% | 0% | 1 |
10 | Medicine, General & Internal | 2 | 3% | 0% | 5 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | CARLO ERBA ERBAMONT GRP CARDIOVASC S | 206321 | 1% | 100% | 1 |
2 | HOLON INTEGRAT CANC | 206321 | 1% | 100% | 1 |
3 | PHYSISOCHEM MED | 206321 | 1% | 100% | 1 |
4 | CHAIR ANGIOL BLOOD COAGULAT | 103160 | 1% | 50% | 1 |
5 | PROGRAM CLIN NUTR | 51579 | 1% | 25% | 1 |
6 | TOKUSHIMA NEW DRUG 3 | 17192 | 1% | 8% | 1 |
7 | GRP RECH LYMPHOMES | 14735 | 1% | 7% | 1 |
8 | PHYS PHARM PHARMACOKINET | 2945 | 1% | 1% | 1 |
9 | HEART GREAT VESSELS ATTILIO REALE | 2904 | 1% | 1% | 1 |
10 | ANGIOL BLOOD COAGULAT | 2643 | 1% | 1% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY | 95945 | 13% | 2% | 19 |
2 | PHARMATHERAPEUTICA | 5889 | 2% | 1% | 3 |
3 | CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL | 5210 | 7% | 0% | 11 |
4 | THROMBOSIS RESEARCH | 2897 | 8% | 0% | 12 |
5 | JOURNAL OF INTERNATIONAL MEDICAL RESEARCH | 2688 | 5% | 0% | 7 |
6 | ACTA PHARMACOLOGICA SINICA | 1787 | 5% | 0% | 7 |
7 | PLATELETS | 1088 | 2% | 0% | 3 |
8 | PHARMACOLOGICAL RESEARCH COMMUNICATIONS | 901 | 1% | 0% | 2 |
9 | ANGIOLOGY | 716 | 3% | 0% | 4 |
10 | COR ET VASA | 612 | 1% | 0% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WISEMAN, LR , FITTON, A , BUCKLEY, MM , (1992) INDOBUFEN - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC EFFICACY IN CEREBRAL, PERIPHERAL AND CORONARY VASCULAR-DISEASE.DRUGS. VOL. 44. ISSUE 3. P. 445-464 | 37 | 74% | 5 |
2 | BHANA, N , MCCLELLAN, KJ , (2001) INDOBUFEN - AN UPDATED REVIEW OF ITS USE IN THE MANAGEMENT OF ATHEROTHROMBOSIS.DRUGS & AGING. VOL. 18. ISSUE 5. P. 369 -388 | 29 | 48% | 16 |
3 | GLOWKA, FK , KARAZNIEWICZ, M , (2004) RESOLUTION OF INDOBUFEN ENANTIOMERS BY CAPILLARY ZONE ELECTROPHORESIS - PHARMACOKINETIC STUDIES OF HUMAN SERUM.JOURNAL OF CHROMATOGRAPHY A. VOL. 1032. ISSUE 1-2. P. 219-225 | 9 | 69% | 9 |
4 | PANG, JX , SUN, LS , WANG, XY , YANG, SQ , SHAN, CW , (1996) EFFECT OF PROCAINAMIDE ON PULMONARY THROMBOEMBOLISM AND PLATELET MALONDIALDEHYDE IN MICE.ACTA PHARMACOLOGICA SINICA. VOL. 17. ISSUE 6. P. 500-502 | 7 | 100% | 1 |
5 | GLOWKA, FK , CALDWELL, J , (2002) PROTEIN BINDING OF INDOBUFEN ENANTIOMERS: PHARMACOKINETICS OF FREE FRACTION - STUDIES AFTER SINGLE OR MULTIPLE DOSES OF RAC-INDOBUFEN.CHIRALITY. VOL. 14. ISSUE 9. P. 736-741 | 8 | 62% | 3 |
6 | DECATERINA, R , SICARI, R , YAN, A , BERNINI, W , GIANNESSI, D , LAZZERINI, G , EFTHYMIOPOULOS, C , STROLINBENEDETTI, M , (1992) THE D-ENANTIOMER FORM OF INDOBUFEN TOTALLY ACCOUNTS FOR THE ANTI-CYCLOOXYGENASE AND ANTIPLATELET ACTIVITY EXVIVO AND FOR THE INCREASE IN BLEEDING-TIME BY INDOBUFEN IN MAN.THROMBOSIS AND HAEMOSTASIS. VOL. 67. ISSUE 2. P. 258-263 | 9 | 75% | 13 |
7 | GRUBB, N , CALDWELL, J , STROLINBENEDETTI, M , (1993) EXCRETION BALANCE AND URINARY METABOLISM OF INDOBUFEN IN RATS AND MICE.BIOCHEMICAL PHARMACOLOGY. VOL. 46. ISSUE 4. P. 759-761 | 8 | 80% | 2 |
8 | LIU, LP , SHAN, CW , LIU, XH , XIAO, HC , YANG, SQ , (1998) EFFECT OF PROCAINAMIDE ON ULTRASTRUCTURE OF BLOOD PLATELET IN RABBITS.ACTA PHARMACOLOGICA SINICA. VOL. 19. ISSUE 4. P. 376-379 | 5 | 100% | 0 |
9 | GLOWKA, FK , STRZELECKA, D , ZAPALSKI, S , (2001) STEADY-STATE PHARMACOKINETICS OF INDOBUFEN ENANTIOMERS IN PATIENTS WITH OBLITERATIVE ATHEROSCLEROSIS.CHIRALITY. VOL. 13. ISSUE 6. P. 308-312 | 6 | 75% | 0 |
10 | DECATERINA, R , GIANNESSI, D , BERNINI, W , LAZZERINI, G , LAVEZZARI, M , STRAGLIOTTO, E , BIAGI, G , COCCHERI, S , (1996) A PROSTACYCLIN-SPARING EFFECT OF INDOBUFEN VS ASPIRIN.THROMBOSIS AND HAEMOSTASIS. VOL. 75. ISSUE 3. P. 510 -514 | 11 | 46% | 6 |
Classes with closest relation at Level 1 |